Evidence map›Paper›PMID 32901445›Full record

Observational studyJournal of gastrointestinal cancer2021

SIRT Compared with DEB-TACE for Hepatocellular Carcinoma: a Real-world Study (the SITAR Study).

Ryan D Hirsch, Chris Mills, Rohit Sawhney, Siddharth Sood, Virginia Bird, Gauri Mishra, Anouk Dev, William Kemp, John Lubel, Stuart K Roberts and 2 more

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Journal of gastrointestinal cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Ryan D HirschEastern Health Clinical School, Monash University, Box Hill, Victoria, Australia. ryandavidhirsch@gmail.com.ORCID http://orcid.org/0000-0003-1283-470X
Chris MillsGastroenterology, Austin Health, Heidelberg, Victoria, Australia.
Rohit SawhneyEastern Health Clinical School, Monash University, Box Hill, Victoria, Australia.
Siddharth SoodGastroenterology and Hepatology, Melbourne Health, Parkville, Victoria, Australia.
Virginia BirdGastroenterology and Hepatology, Melbourne Health, Parkville, Victoria, Australia.
Gauri MishraGastroenterology, Monash Health, Clayton, Victoria, Australia.
Anouk DevGastroenterology, Monash Health, Clayton, Victoria, Australia.
William KempGastroenterology, Alfred Health, Melbourne, Victoria, Australia.
John LubelGastroenterology, Alfred Health, Melbourne, Victoria, Australia.
Stuart K RobertsGastroenterology, Alfred Health, Melbourne, Victoria, Australia.
Paul GowGastroenterology, Austin Health, Heidelberg, Victoria, Australia.
Amanda J NicollEastern Health Clinical School, Monash University, Box Hill, Victoria, Australia.
Alfred Health · AUBox Hill Hospital · AUAustin Health · AUMelbourne Health · AUMonash Health · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) is responsible for 1% of deaths worldwide, and the incidence continues to increase. Despite surveillance programs, 70% of HCC patients are not suitable for curative options at diagnosis, and therefore, non-curative treatments are essential to modern clinical practice. There are many novel treatments, though their roles are not well defined. This study aimed to contrast Selective Internal Radiation Therapy (SIRT) and Drug Eluting Bead Transarterial Chemoembolisation (DEB-TACE) to further define their roles.

methodsThis was a retrospective multicentre cohort study. Factors included for analysis were type of HCC treatment, number of lesions, lesion size, multiple disease severity scores, cirrhosis and vascular invasion. The primary endpoint was transplant-free survival.

resultsTransplant-free survival was similar between the two cohorts (p = 0.654), despite a variation in median lesion size, SIRT: 54.5 mm, DEB-TACE: 34 mm (p ≤ 0.001). A univariate Cox proportional hazard model utilising treatment modality as the covariate showed no significant difference in survival (DEB-TACE HR 1.4 (95%CI 0.85-2.15 p = 0.207). The size of the largest lesion was the best predictor of 3-year survival (p = 0.035). Lesion size was inversely associated with survival (HR 1.01 (95%CI 1-1.02, p = 0.025)) on multivariate analysis.

conclusionThis study is the first to catalogue the experience of using SIRT in HCC in a real-world Australian population. It has demonstrated no difference in survival outcomes between DEB-TACE and SIRT. Further, it has shown SIRT to be a reasonable alternative to DEB-TACE especially in larger lesions and has demonstrated that DEB-TACE has a role in select patients with advanced disease.

Indexed as

AgedAged, 80 and overAustraliaCarcinoma, HepatocellularChemoembolization, TherapeuticCohort StudiesDisease-Free SurvivalFemaleHumansLiver NeoplasmsMaleMiddle AgedRetrospective StudiesTreatment OutcomeYttrium RadioisotopesYttrium RadioisotopesDrug eluting bead chemoembolisationHepatocellular carcinomaIntra-arterial therapyLiver cancerSelective internal radiation therapyTransarterial radiation therapy

Identifiers

PMID32901445
OpenAlexW3084875221

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.